Compare MIRM & ASB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MIRM | ASB |
|---|---|---|
| Founded | 2018 | 1861 |
| Country | United States | United States |
| Employees | N/A | 4000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.4B |
| IPO Year | 2019 | N/A |
| Metric | MIRM | ASB |
|---|---|---|
| Price | $106.24 | $27.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 12 |
| Target Price | ★ $119.85 | $29.75 |
| AVG Volume (30 Days) | 667.9K | ★ 1.8M |
| Earning Date | 05-06-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.45% |
| EPS Growth | ★ 74.59 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,138,000.00 | N/A |
| Revenue This Year | $26.22 | $21.24 |
| Revenue Next Year | $22.04 | $8.86 |
| P/E Ratio | ★ N/A | $10.23 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.89 | $22.40 |
| 52 Week High | $112.00 | $29.52 |
| Indicator | MIRM | ASB |
|---|---|---|
| Relative Strength Index (RSI) | 62.25 | 52.75 |
| Support Level | $87.26 | $23.96 |
| Resistance Level | $107.51 | $28.02 |
| Average True Range (ATR) | 5.87 | 0.63 |
| MACD | 0.98 | -0.08 |
| Stochastic Oscillator | 75.13 | 38.61 |
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Associated Banc-Corp is a bank holding company based in the United States of America. The company, through its subsidiaries, provides a broad array of banking and non-banking products and services to individuals and businesses. The group operates in three reportable segments: Corporate and Commercial Specialty; Community, Consumer, and Business; and Risk Management and Shared Services. The majority of its revenue is derived from the Corporate and Commercial Specialty segment, which serves a wide range of customers, including larger businesses, developers, not-for-profits, municipalities, and financial institutions by providing lending and deposit solutions as well as support to deliver, fund, and manage such banking solutions.